首页> 外国专利> use of riluzole combined with appropriate auxiliary and additives for the treatment of diseases caused by a hyperproliferation of keratinocytes are markedin particular, neurodermatitis and psoriasis

use of riluzole combined with appropriate auxiliary and additives for the treatment of diseases caused by a hyperproliferation of keratinocytes are markedin particular, neurodermatitis and psoriasis

机译:利鲁唑与适当的辅助剂和添加剂结合使用在治疗由角质形成细胞过度增殖引起的疾病中的用途尤其明显,例如神经性皮炎和牛皮癣

摘要

In the production of a medicament for the prevention of a disease characterized by hyperproliferation of keratinocytes and/or T cells, Riluzole (I) or its salts, and optionally adjuvants and additives are used. Independent claims are included for: (1) a composition (C1) comprising (I) and active ingredients or calcineurin antagonists; and (2) topical medicament (M1) for transdermal delivery comprising (I) and a topical excipient. ACTIVITY : Cytostatic; Dermatological; Antipsoriatic; Keratolytic; Antiinflammatory; Immunosuppressive; Antilichen; Antiallergic; Antiseborrheic; Antiparkinsonian; Muscular-Gen.; Neuroprotective; Neuroleptic; Sedative; Antidepressant; Analgesic; Tranquilizer; Vulnerary; Cerebroprotective; Auditory; Relaxant; Anticonvulsant; Hypnotic. The effect of Riluzole on the proliferation of keratinocytes was examined on the basis of Ha-CaT cells as follows. 5 X 10 3Ha-CaT keratinocytes were seeded into 60 wells of a 96 well-plate in KBM/10% FCS (200 Microl) and incubated for 24 hours at 37[deg]C. After incubation of 6 wells with Ha-CaT cells and 1 well without cells were treated for 48 hours with negative control (KMB/1% DMSO), positive control (KBM/FCS/1% DMSO) or with Riluzole (250 Micromol) in KBM/FCS (100 mmol/l in DMSO) and incubated for 48 hours at 37[deg]C. The concentration of DMSO was kept constant at 1% at all tested Riluzole concentrations. At the end of the second incubation period the medium was removed and the proliferation of cells was determined with the Cell Titer Viability Assay. The results showed that Riluzole completely inhibited proliferation of keratinocytes with values comparable with that achieved with the negative control. MECHANISM OF ACTION : Hyperproliferation of keratinocytes and/or T cells inhibitor.
机译:在制备用于预防特征在于角质形成细胞和/或T细胞过度增殖的疾病的药物中,使用利鲁唑(I)或其盐,以及任选地佐剂和添加剂。包括以下独立权利要求:(1)一种组合物(C1),其包含(I)和活性成分或钙调神经磷酸酶拮抗剂。 (2)透皮递送的局部药物(M1),其包含(I)和局部赋形剂。活动:细胞抑制;皮肤;对牛皮癣;角质分解;消炎(药;免疫抑制Antilichen;抗过敏;抗脂溢性;反帕金森病;肌肉型;具有神经保护作用;抗精神病药;镇静剂;抗抑郁药止痛药镇静剂;伤药;脑保护听觉轻松;抗惊厥药;催眠。根据Ha-CaT细胞,如下检测利鲁唑对角质形成细胞增殖的作用。将5×10 3> Ha-CaT角质形成细胞接种到96孔板的60孔中的KBM / 10%FCS(200微升)中,并在37℃下孵育24小时。将带有Ha-CaT细胞的6孔和没有细胞的1孔孵育后,在阴性对照(KMB / 1%DMSO),阳性对照(KBM / FCS / 1%DMSO)或利鲁唑(250 Micromol)中孵育48小时。 KBM / FCS(在DMSO中为100mmol / l),并在37℃下孵育48小时。在所有测试的利鲁唑浓度下,DMSO的浓度保持恒定在1%。在第二温育期结束时,除去培养基,并通过细胞滴度活力测定法测定细胞的增殖。结果表明,利鲁唑完全抑制了角质形成细胞的增殖,其值与阴性对照相当。作用机理:角质形成细胞和/或T细胞抑制剂的过度增殖。

著录项

  • 公开/公告号DE50304744D1

    专利类型

  • 公开/公告日2006-10-05

    原文格式PDF

  • 申请/专利权人 BIOFRONTERA BIOSCIENCE GMBH;

    申请/专利号DE20035004744T

  • 发明设计人 SYCH MICHAEL;GOPPELT ANDREAS;

    申请日2003-04-28

  • 分类号A61K31/428;A61K45/06;A61P17;A61P17/06;A61P25;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;

  • 国家 DE

  • 入库时间 2022-08-21 21:19:21

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号